A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in ABO-Incompatible Liver Transplantation

Inclusion Criteria: * Completed informed consent process * Male or female aged ≥19 years and \<75 years * Patients scheduled hospitalization for liver transplantation Exclusion Criteria: * Patients who are scheduled or have history of re-transplantation or multiorgan transplantation * Patients receiving living donor in emergency * Patients with Donor Specific Antibody (DSA) ≥ MFI 10,000 or Human Leukocyte Antigen (HLA) crossmatch (+) cytotoxic T-cell ≥ 1:32 * Patients with a history of biliary tract disease * Patients who plasma exchange is forbidden (with a history of allergic or anaphylactic reaction to FFP, albumin, heparin, etc.) * Patients with a history of specific medical conditions * Severe renal failure (eGFR \< 30 mL/min/1.73 m\^2 at screening) * Deep Vein Thrombosis (DVT) or thrombotic complications from Intravenous Immunoglobulin (IVIg) therapy * Cerebrovascular or cardiovascular disease (Hyperviscosity syndrome, Transient Ischemic Attack (TIA), Stroke, Thromboembolism, Unstable angina, etc.) * Clinical state causing secondary immunodeficiency (Leukemia, Lymphoma, Multiple myeloma, HIV infection, Chronic or Cyclic neutropenia (Absolute neutrophil \< 500/mm\^3), etc.) * Uncontrolled hypertension (Systolic blood pressure \> 160 mmHg or Diastolic blood pressure \> 100 mmHg) * Hemolytic or hemorrhagic anemia * Decreased cardiac functions * Bacterial, fungal or viral infection making liver transplantation forbidden * Intraductal or vascular infiltration observed in patients with hepatocellular carcinoma using medical imaging before liver transplantation * Patients metastasized to organs except for liver or diagnosed cancer except for liver cancer and squamous cell carcinoma within 5 years from screening * Patients with sepsis * Patients who had interventional therapy in blood vessels (hepatic vein, portal vein, hepatic artery, etc.) or bile ducts before LDLT * Patients who have allergy or hypersensitivity to blood products, blood-derived products, IVIg or immunoglobulin G (IgG) products * Patients who have immunoglobulin A (IgA) deficiency or anti-IgA antibody * Patients who are pregnant and nursing * Patients unwilling to use adequate method of contraception (hormonal methods, intrauterine device or intrauterine system, vasectomy, tubal ligation, etc.) during this study * Patients who had received other investigational products within 8 weeks from complete consent or who are scheduled to receive other investigational products during this study * Others whom the investigator considers ineligible for the study.